Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solasia Pharma KKSTU:9SO 53 PS Ratio is 17.13 as of Aug. 28, 2026, which is 48% below its 10-year median of 32.94. GuruFocus rates STU:9SO with a GF Score™ of 53/100 and a GF Value™ of €0.14 (Fairly Valued). The stock has 5 warning signs investors should review. Among 951 Drug Manufacturers companies, Solasia Pharma KK ranks worse than 93.06% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Solasia Pharma KK's share price is €0.137.
Solasia Pharma KK's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €0.01. Hence, Solasia Pharma KK's PS Ratio for today is 17.13.
The historical rank and industry rank for Solasia Pharma KK's PS Ratio or its related term are showing as below:
STU:9SO'
s PS Ratio Range Over the Past 10 Years
Min: 5.01 Med: 32.94 Max: 209.3
Current: 19.39
During the past 13 years, Solasia Pharma KK's highest PS Ratio was 209.30. The lowest was 5.01. And the median was 32.94.
STU:9SO's PS Ratio is ranked worse than 93.06% of 951
companies
in the Drug Manufacturers industry
Industry Median: 2.38
vs STU:9SO: 19.39
Solasia Pharma KK revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Solasia Pharma KK was 182.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -39.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -21.00% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -13.30% per year.
During the past 13 years, Solasia Pharma KK's highest 3-Year average Revenue per Share Growth Rate was 227.40% per year. The lowest was -39.00% per year. And the median was -8.10% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Solasia Pharma KK PS Ratio Related Terms
Solasia Pharma KK PS Ratio Historical Data
* Premium members only.
The historical data trend for Solasia Pharma KK's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solasia Pharma KK's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solasia Pharma KK PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solasia Pharma KK's PS Ratio distribution charts can be found below:
* The bar in red indicates where Solasia Pharma KK's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Solasia Pharma KK's Share Price of today is €0.137. Solasia Pharma KK's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Solasia Pharma KK (STU:9SO) has a PS Ratio of 17.13 as of Aug. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Solasia Pharma KK and its competitors. This is 48% below median its historical median of 32.94. Over the past decade, Solasia Pharma KK's PS Ratio has ranged from 5.01 to 209.30. According to the industry distribution chart, Solasia Pharma KK ranks #885 out of 951 companies in the Drug Manufacturers industry, placing it in the top 93.1%.
Is Solasia Pharma KK's PS Ratio too high?
Solasia Pharma KK's current PS Ratio of 17.13 is 48% below median its 10-year median of 32.94. Over the past 10 years, this metric has ranged from a low of 5.01 to a high of 209.30. The Drug Manufacturers industry median PS Ratio is 2.38. Solasia Pharma KK's value of 17.13 is 619.7% above this industry median. Based on the distribution chart, Solasia Pharma KK ranks #885 out of 951 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Solasia Pharma KK has a GF Score™ of 53/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's PS Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Solasia Pharma KK ranks #885 out of 951 companies for PS Ratio. This places Solasia Pharma KK in the lower half of its industry. The industry median PS Ratio is 2.38. Solasia Pharma KK's value of 17.13 is 619.7% above this benchmark. Historically, Solasia Pharma KK's own PS Ratio has ranged from 5.01 to 209.30 over the past decade. While the company's 10-year median is 32.94 vs. the industry median of 2.38, Solasia Pharma KK has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.38, based on 951 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solasia Pharma KK's current PS Ratio of 17.13 is 619.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Solasia Pharma KK and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solasia Pharma KK's current PS Ratio is 17.13, which is 48% below median its own 10-year median of 32.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (STU:9SO) is currently considered Fairly Valued. The stock's GF Value™ is €0.14, compared to a current price of €0.14 — trading 2.1% below its estimated fair value. The current PS Ratio is 17.13, which is 48% below median its 10-year median of 32.94 and 619.7% above the Drug Manufacturers industry median of 2.38. Solasia Pharma KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Solasia Pharma KK (STU:9SO), the current PS Ratio is 17.13 as of Aug. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solasia Pharma KK (STU:9SO) Overvalued in 2026?
Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be undervalued.
The current stock price of €0.14 is trading 2.1% below its estimated GF Value™ of €0.14.
GuruFocus considers Solasia Pharma KK to be Fairly Valued.
Key valuation signals for STU:9SO:
PS Ratio: 17.13 (48% below median its 10-year median of 32.94)
GF Value™: €0.14 vs. price of €0.14 (2.1% below fair value)
Industry Position: 619.7% above the Drug Manufacturers median (#885 of 951)
No single metric tells the full story. See the STU:9SO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:9SO has been successfully added to your 
